These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11052785)

  • 41. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
    Kleinman EF; Campbell E; Giordano LA; Cohan VL; Jenkinson TH; Cheng JB; Shirley JT; Pettipher ER; Salter ED; Hibbs TA; DiCapua FM; Bordner J
    J Med Chem; 1998 Jan; 41(3):266-70. PubMed ID: 9464356
    [No Abstract]   [Full Text] [Related]  

  • 42. KF19514, a phosphodiesterase 4 and 1 inhibitor, inhibits TNF-alpha-induced GM-CSF production by a human bronchial epithelial cell line via inhibition of PDE4.
    Sasaki K; Manabe H
    Inflamm Res; 2004 Jan; 53(1):31-7. PubMed ID: 15021978
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel cyclic compounds as potent phosphodiesterase 4 inhibitors.
    He W; Huang FC; Hanney B; Souness J; Miller B; Liang G; Mason J; Djuric S
    J Med Chem; 1998 Oct; 41(22):4216-23. PubMed ID: 9784096
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phosphodiesterase 4 isoenzyme inhibitory activity of 3-phenylxanthines and 4-pheny.
    Suzuki H; Sawanishi H; Yamamoto K; Yokogawa K; Miyamoto K
    Chem Pharm Bull (Tokyo); 2001 Feb; 49(2):188-91. PubMed ID: 11217107
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor.
    Aoki M; Fukunaga M; Sugimoto T; Hirano Y; Kobayashi M; Honda K; Yamada T
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1142-9. PubMed ID: 11504812
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
    Banner KH; Trevethick MA
    Trends Pharmacol Sci; 2004 Aug; 25(8):430-6. PubMed ID: 15276712
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New orally active PDE4 inhibitors with therapeutic potential.
    Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
    Bioorg Med Chem; 2004 Aug; 12(15):4089-100. PubMed ID: 15246087
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones.
    Van der Mey M; Boss H; Hatzelmann A; Van der Laan IJ; Sterk GJ; Timmerman H
    J Med Chem; 2002 Jun; 45(12):2520-5. PubMed ID: 12036360
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents.
    Van der Mey M; Bommelé KM; Boss H; Hatzelmann A; Van Slingerland M; Sterk GJ; Timmerman H
    J Med Chem; 2003 May; 46(10):2008-16. PubMed ID: 12723963
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294.
    Gale DD; Hofer P; Spina D; Seeds EA; Banner KH; Harrison S; Douglas G; Matsumoto T; Page CP; Wong RH; Jordan S; Smith F; Banik N; Halushka PV; Cavalla D; Rotshteyn Y; Kyle DJ; Burch RM; Chasin M
    Pulm Pharmacol Ther; 2003; 16(2):97-104. PubMed ID: 12670778
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis.
    Robichaud A; Stamatiou PB; Jin SL; Lachance N; MacDonald D; Laliberté F; Liu S; Huang Z; Conti M; Chan CC
    J Clin Invest; 2002 Oct; 110(7):1045-52. PubMed ID: 12370283
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison of the inhibitory activity of selective PDE4 inhibitors on eosinophil recruitment in guinea pig skin.
    Teixeira MM; Miotla JM; Cooper N; Gristwood RW; Hellewell PG
    Mem Inst Oswaldo Cruz; 1997; 92 Suppl 2():193-6. PubMed ID: 9698932
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.
    Andrés JI; Alonso JM; Díaz A; Fernández J; Iturrino L; Martínez P; Matesanz E; Freyne EJ; Deroose F; Boeckx G; Petit D; Diels G; Megens A; Somers M; Van Wauwe J; Stoppie P; Cools M; De Clerck F; Peeters D; de Chaffoy D
    Bioorg Med Chem Lett; 2002 Feb; 12(4):653-8. PubMed ID: 11844693
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
    Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
    J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Experimental studies on guanosine 3',5'-cyclic monophosphate levels and airway responsiveness of the novel phosphodiesterase type 5 inhibitor SR 265579 in guinea-pigs.
    Kapui Z; Schaeffer P; Mikus EG; Boronkay E; Gyürky J; Herbert JM; Pascal M
    Arzneimittelforschung; 1999 Aug; 49(8):685-93. PubMed ID: 10483515
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Orally active PDE4 inhibitors with therapeutic potential.
    Ochiai H; Ohtani T; Ishida A; Kishikawa K; Obata T; Nakai H; Toda M
    Bioorg Med Chem Lett; 2004 Mar; 14(5):1323-7. PubMed ID: 14980691
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
    Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
    Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents.
    Doherty AM
    Curr Opin Chem Biol; 1999 Aug; 3(4):466-73. PubMed ID: 10419856
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel selective phosphodiesterase (PDE4) inhibitors. 4. Resolution, absolute configuration, and PDE4 inhibitory activity of cis-tetra- and cis-hexahydrophthalazinones.
    Van der Mey M; Boss H; Couwenberg D; Hatzelmann A; Sterk GJ; Goubitz K; Schenk H; Timmerman H
    J Med Chem; 2002 Jun; 45(12):2526-33. PubMed ID: 12036361
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.
    Gallant M; Chauret N; Claveau D; Day S; Deschênes D; Dubé D; Huang Z; Lacombe P; Laliberté F; Lévesque JF; Liu S; Macdonald D; Mancini J; Masson P; Mastracchio A; Nicholson D; Nicoll-Griffith DA; Perrier H; Salem M; Styhler A; Young RN; Girard Y
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1407-12. PubMed ID: 18207397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.